Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand

被引：0
|
作者：
Junhui Yu
Kui Yang
Jianbao Zheng
Wei Zhao
Xuejun Sun
机构：
[1] First Affiliated Hospital of Xi’an Jiaotong University,Department of General Surgery
来源：
Cancer Gene Therapy | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：871 / 872
页数：1
相关论文
共 50 条
  • [41] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
    Kowdley, Kris V.
    Luketic, Velimir A.
    Jones, David E.
    Chapman, Roger W.
    Burroughs, Andrew K.
    Hirschfield, Gideon M.
    Poupon, Raoul
    Schramm, Christoph
    Vincent, Catherine
    Rust, Christian
    Pares, Albert
    Mason, Andrew L.
    Castelloe, Erin N.
    Sciacca, Cathi I.
    Boehm, Olaf
    Pruzanski, Mark
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 416A - 417A
  • [42] Inhibition of farnesoid X receptor-induced BSEP gene expression by ligand-activated vitamin D receptor.
    Honjo, Y
    Kobayashi, Y
    Sasaki, S
    Misawa, H
    Nakamura, H
    HEPATOLOGY, 2004, 40 (04) : 492A - 492A
  • [43] Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3
    Fan, Yuan-Yuan
    Ding, Wen
    Zhang, Cheng
    Fu, Lin
    Xu, De-Xiang
    Chen, Xi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 77
  • [44] Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury
    Zhu, Jin-Bo
    Xu, Shen
    Li, Jun
    Song, Jin
    Luo, Biao
    Song, Ya-Ping
    Zhang, Zhi-Hui
    Chen, Yuan-Hua
    Xie, Dong-Dong
    Yu, De-Xin
    Xu, De-Xiang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 838 : 60 - 68
  • [45] Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
    Adorini, Luciano
    Rigbolt, Kristoffer
    Feigh, Michael
    Roth, Jonathan
    Erickson, Mary
    PLOS ONE, 2024, 19 (04):
  • [46] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, Gideon M.
    Mason, Andrew L.
    Gordon, Stuart C.
    Luketic, Velimir A.
    Mayo, Marlyn
    Vincent, Catherine
    Lindor, Keith D.
    Pares, Albert
    Kowdley, Kris V.
    Trauner, Michael
    Esguerra, Maria
    Boehm, Olaf
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 429A - 429A
  • [47] FURTHER INCREASE IN BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY BY OBETICHOLIC ACID, A FARNESOID-X-RECEPTOR AGONIST
    Di Pasqua, L. G.
    Berardo, C.
    Rizzo, V.
    Adorini, L.
    Richelmi, P.
    Vairetti, M.
    Ferrigno, A.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E55 - E55
  • [48] OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASE
    不详
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S2
  • [49] THE FARNESOID-X-RECEPTOR AGONIST OBETICHOLIC ACID FURTHER INCREASES BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY
    Di Pasqua, L. G.
    Berardo, C.
    Rizzo, V.
    Adorini, L.
    Richelmi, P.
    Vairetti, M.
    Ferrigno, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S315 - S315
  • [50] Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma
    Gong, Yihang
    Li, Kun
    Qin, Yunfei
    Zeng, Kaining
    Liu, Jianrong
    Huang, Shaozhuo
    Chen, Yewu
    Yu, Haoyuan
    Liu, Wei
    Ye, Linsen
    Yang, Yang
    FRONTIERS IN ONCOLOGY, 2021, 11
12345